In vivo, experiments on CHO/Trop2 and MCF7 xenografts showed that TrMab-6 significantly reduced tumor growth but had no antitumor activity against parental CHO-K1 and MCF7/Trop2-knockout xenografts. Here, TACSTD2 is linked to neoplasm.